Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869738 | 0.84 | HRH4 (0.53) | HTR2BHTR7HTR1ADRD2HTR2A | |
| SCHEMBL2451092 | 0.82 | APP (0.64) | HTR2BACKR3CDK9HTR7APP | |
| SCHEMBL14869438 | 0.79 | HTR7 (0.60) | HTR2BACKR3CDK9HTR7HTR6 | |
| SCHEMBL29609013 | 0.79 | HTR7 (0.60) | HTR2BACKR3CDK9HTR7HTR6 | |
| SCHEMBL22151175 | 0.77 | APP (0.64) | HTR1AAPPLMNAADORA2A | |
| SCHEMBL14869762 | 0.77 | HRH4 (0.48) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL1938196 | 0.76 | HTR7 (0.56) | HTR2BACKR3CDK9HTR7APP | |
| SCHEMBL4376781 | 0.74 | APP (0.49) | HTR2BACKR3APPHDAC1ADORA2A | |
| SCHEMBL14869876 | 0.74 | HRH4 (0.48) | HTR2BLMNACA1CA2CA9 | |
| SCHEMBL6727019 | 0.74 | NPSR1 (0.74) | HTR2BHTR1AAPPCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | claimed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | claimed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | claimed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | claimed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | claimed |
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032199-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | HTR2B 5/4885ACKR3 462/4885CDK9 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.